Genflow Biosciences PLC (LSE: GENF), a leading company in the field of longevity, has revealed plans to reorganize its primary board of directors and scientific advisory board (SAB) in order
OKYO Pharma is scheduled to present data on their dry eye drug at an important conference.
OKYO Pharma Ltd (LSE: OKYO, NASDAQ: OKYO), a biopharmaceutical company focused on ophthalmology, is set to present two papers on their treatment for dry eye disease (DED), OK-101, at the
hVIVO PLC Annual Report and Notice of AGM
hVIVO plc (AIM & Euronext: HVO), formerly known as Open Orphan plc, and a global leader in conducting human challenge clinical trials for infectious and respiratory disease products, has announced
Novacyt S.A. Final Results, Full year revenue and EBITDA
Novacyt (EURONEXT GROWTH: ALNOV; AIM: NCYT), a clinical diagnostics company, has announced its audited results for the year ended 31 December 2022.
Avacta Group PLC has announced that the first patient has been dosed in the US in the AVA6000 Phase 1 trial.
Avacta Group plc, a life sciences company that develops targeted oncology drugs and diagnostics, has dosed the first patient in the US as part of its phase 1 multi-center trial
GSK’s shares have opened higher after sales and profits for the first quarter exceeded expectations.
GSK’s shares rose at the opening of trading after the company reported that its Q1 revenue and profits had exceeded expectations, driven by the success of its Shingrix shingles vaccine.
hVIVO PLC FDA Breakthrough and Fast Track for US biotech
SAB Biotherapeutics’ investigational therapeutic for the treatment of seasonal influenza, SAB-176, has been granted both Breakthrough Therapy and Fast Track designations by the US Food and Drug Administration (FDA).
OKYO Pharma is all set to commence a clinical trial for dry eye treatment in the US
Activation of First Clinical Trial Site in the U.S
N4 Pharma PLC (AIM:N4P) siRNA update
N4 Pharma Plc (AIM: N4P), the specialist pharmaceutical company developing Nuvec®, a novel delivery system for cancer treatments and vaccines, is pleased to provide a further update on its ongoing
hVIVO PLC (AIM:HVO) Final results
Transformational year with record EBITDA underlining strong operational delivery
Avacta Group PLC (AIM:AVCT) Preliminary Results for the year ended 31 December 2022
A period of continued significant progress